Lipoic Acid for Neuroprotection in Secondary Progressive Multiple Sclerosis

被引:0
|
作者
Spain, Rebecca [1 ,2 ]
Murchison, Charles
Horak, Fay [1 ]
Simon, Jack
Bourdette, Dennis [1 ]
机构
[1] OHSU, Portland, OR USA
[2] Portland VA Hlth Care Syst, Neurol, Portland, OR USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P1.373
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Spinal myoclonus in secondary progressive multiple sclerosis
    Raisa, N.
    MOVEMENT DISORDERS, 2021, 36 : S118 - S118
  • [32] Macrophage Recruitment in Secondary Progressive Multiple Sclerosis
    Hanael, Erez
    Rothmann, Tali
    Falb, Rina
    Gurevich, Michael
    Achiron, Anat
    NEUROLOGY, 2012, 78
  • [33] Management of secondary-progressive multiple sclerosis
    Giovannoni, G
    CNS DRUGS, 2004, 18 (10) : 653 - 669
  • [34] Secondary Progressive Multiple Sclerosis New Insights
    Cree, Bruce A. C.
    Arnold, Douglas L.
    Chataway, Jeremy
    Chitnis, Tanuja
    Fox, Robert J.
    Ramajo, Angela Pozo
    Murphy, Niamh
    Lassmann, Hans
    NEUROLOGY, 2021, 97 (08) : 378 - 388
  • [35] Siponimod: A Review in Secondary Progressive Multiple Sclerosis
    Scott, Lesley J.
    CNS DRUGS, 2020, 34 (11) : 1191 - 1200
  • [36] Parkinsonism secondary to primary progressive multiple sclerosis
    Gallardo, M.
    Soto, A.
    MOVEMENT DISORDERS, 2010, 25 (07) : S498 - S498
  • [37] Siponimod for the treatment of secondary progressive multiple sclerosis
    Dumitrescu, Laura
    Constantinescu, Cris S.
    Tanasescu, Radu
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 143 - 150
  • [38] Secondary Progressive Multiple Sclerosis: Definition and Measurement
    Domenico Plantone
    Floriana De Angelis
    Anisha Doshi
    Jeremy Chataway
    CNS Drugs, 2016, 30 : 517 - 526
  • [39] Siponimod to treat secondary progressive multiple sclerosis
    Gajofatto, A.
    Turatti, M.
    DRUGS OF TODAY, 2020, 56 (01) : 37 - 46
  • [40] Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
    Floriana De Angelis
    Domenico Plantone
    Jeremy Chataway
    CNS Drugs, 2018, 32 : 499 - 526